Sun Pharma to manufacture and market Semaglutide in South Africa; shares trade in green

Shares of Sun Pharmaceutical opened in green on Wednesday after the company secured major approval to manufacture and market Semaglutide in South Africa. The shares have rallied over 13% in 2026 on a YTD basis.

The company said through the exchange filing that “ Sun Pharmaceutical Industries Limited announced that it has received approval from the South African Health Products Regulatory Authority (SAHPRA) to manufacture and market a generic version of semaglutide injection in South Africa for the treatment of adults with inadequately controlled type 2 diabetes mellitus as an adjunct to diet and exercise”.

Commenting on the development, Chief Operating Officer Aalok Shanghvi said, “ South Africa is the second market after India where Sun Pharma has received approval for generic semaglutide. This reflects our ability to develop complex generic medicines that meet the stringent quality standards across different markets. We remain committed to improving access to generics and making evidence-based treatment options available to patients and healthcare professionals ”.

The company plans to launch the product in the South African market in the coming days, and it will be available in a pre-filled, multi-dose injectable pen in two strengths (2 mg/1.5 mL and 4 mg/3 mL).

Earlier in June, the company announced the acquisition of Innovacare Lifesciences. The deal is worth around ₹271.2 crore. This strategic investment is aimed at strengthening the product portfolio of the company. The transaction is expected to be completed on or before July 31, 2026.